The EHBP1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung carcinoma cell line. This product enables targeted disruption of the EHBP1 gene, generating a loss-of-function model for investigating EHBP1-mediated cellular processes. The polyclonal nature of the knockout pool provides a broad representation of gene-disrupted alleles, making it suitable for functional genomics screens and pathway analyses without the clonal variation associated with single-cell-derived lines.
The A-549 parental cell line was originally established from the lung adenocarcinoma of a 58-year-old Caucasian male. These cells exhibit epithelial morphology and are widely employed as a model system for studying lung adenocarcinoma biology, including oncogenic signaling, cellular trafficking, and metastatic behavior. The adherent growth and robust transfection efficiency of A-549 cells further enhance their utility in gene-editing applications, enabling effective delivery of CRISPR/Cas9 components and subsequent selection of knockout populations.
EHBP1 (EH domain-binding protein 1) functions as a critical adaptor linking endocytic vesicle formation to actin cytoskeleton dynamics. It is activated by upstream signals such as EGF and small GTPases, and directly interacts with Eps15 via its EH domain. This interaction couples EHBP1 to the clathrin-mediated endocytosis machinery. Downstream, EHBP1 regulates Rab10-mediated endosomal tubulation and promotes localized actin polymerization, which is essential for endosomal trafficking and cell migration. The EHBP1 signaling axis, including Eps15, Rab10, and actin, integrates membrane trafficking with cytoskeletal remodeling, influencing processes such as cell adhesion and motility.
In the context of A-549 lung adenocarcinoma, loss of EHBP1 likely disrupts coordination between endocytosis and the actin cytoskeleton, potentially impairing cell migration, invasion, and metastatic potential. As EHBP1 has been implicated in multiple cancer types including colorectal cancer, glioblastoma, and prostate cancer, this knockout model is valuable for dissecting its role in tumor progression. The polyclonal nature of the knockout pool enables robust assessment of EHBP1 function in oncogenic signaling cascades and may reveal synthetic lethal interactions or vulnerabilities specific to lung adenocarcinoma.
Researchers can utilize these cells in a variety of assays to explore endocytosis-actin crosstalk, cancer cell invasion, and drug-screening applications. Typical experimental approaches include Western blotting to confirm protein loss, immunofluorescence and actin staining to visualize cytoskeletal alterations, endocytosis assays to monitor trafficking dynamics, and migration/invasion assays to assess metastatic behavior. Co-immunoprecipitation can further validate protein-protein interactions with known partners such as Eps15 and Rab10. For further information or technical support, please contact Ascent Research.
